Quick viewing(Text Mode)

Commonly Prescribed HIV Medications

Commonly Prescribed HIV Medications

Commonly Prescribed HIV

Single-Tablet Regimens Atripla Biktarvy Complera Delstrigo Dovato Genvoya Juluca Odefsey Stribild Sym /Sym Lo (// (/emtricitabine/ (/emtricitabine/ (// ( + lamivudine) (// (dolutegravir/rilpivirine) (emtricitabine/rilpivirine/ (elvitegravir/cobicistat/ (efavirenz/lamivudine/ fumarate) ) tenofovir disoproxil fumarate) tenofovir disoproxil fumarate) emtricitabine/ tenofovir alafenamide) emtricitabine/tenofovir tenofovir disoproxil fumarate) tenofovir alafenamide) disoproxil fumarate)

Single-Tablet Regimens (cont.) Nucleoside/Nucleotide Analogs (NRTIs) Symtuza Triumeq Cimduo/Temixys Descovy Emtriva Epivir Epzicom Truvada Viread Ziagen (/cobicistat/ (dolutegravir// (lamivudine/tenofovir (emtricitabine/tenofovir (emtricitabine or FTC) (lamivudine or 3TC) (abacavir/lamivudine) (emtricitabine/tenofovir (tenofovir disoproxil (abacavir or ABC) emtricitabine/tenofovir lamivudine) disoproxil fumarate) alafenamide) disoproxil fumarate) fumarate or TDF) alafenamide)

Protease Inhibitors (PIs) Non-Nucleosides (NNRTIs) Evotaz Prezcobix Prezista Reyataz Edurant Intelence Pifeltro Sustiva (/cobicistat) (darunavir/cobicistat) (darunavir or DRV) (atazanavir or ATV) (rilpivirine or RPV) ( or ETV) (doravirine) (efavirenz or EFV)

Pre-Exposure Prophylaxis (PrEP) Integrase Inhibitors Pharmacokinetic Enhancers Entry Inhibitors Truvada Descovy Isentress Tivicay Norvir Tybost Selzentry Trogarzo (emtricitabine/tenofovir (emtricitabine/tenofovir ( or RAL) (dolutegravir or DTG) ( or RTV) (cobicistat) ( or MVC) (-uiyk) disoproxil fumarate) alafenamide)

Not indicated for individuals at risk (for injection) from receptive vaginal sex. HIV Life Cycle and Action Sites Community Research Initiative of New England (CRI) is an independent, nonpro t, community-based organization dedicated to Protease inhibitors ending the HIV epidemic through: • Research: Conducting HIV/AIDS and hepatitis C clinical trials. Maturation • Prevention: Limiting new HIV cases through education and access Attachment Budding to biomedical prevention strategies like PrEP. Env • Access to Treatment: Providing access to medications, health Co-receptor Virus antagonists assembly insurance coverage, and health bene ts information to people who have infectious diseases. CD4 • Impact: Disseminating state-of-the-art treatment and insurance Gene CCR5 training and consultation. Fusion inhibitors or CXCR4 expression Since 1989, CRI has produced critical data that has contributed to the FDA approval of nearly all of the currently available HIV treatments and forever NRTIs, changed the direction of HIV/AIDS treatment around the world. NNRTIs InSTIs, HIV ALLINIs Through its management of the Massachusetts Infectious Disease Drug Nucleus Assistance Program (IDDAP), CRI provides access to medications and health Medication Chart Reverse insurance coverage to more than 8,000 Massachusetts residents living with Current as of 11/19 Fusion transcription Integration HIV or taking preventive treatment. Through its continued outreach eorts, CRI provides the latest treatment information to people living with HIV, Simpli ed diagram showing human immunode ciency virus (HIV) replication and the mechanisms of action of antiretroviral drug classes. hepatitis C, and other infectious diseases. About the medication chart Less Frequently Prescribed HIV Medications CRI produces the medication chart with funding from the Bureau of Infectious Disease, Oce of HIV/AIDS, Massachusetts Department of Public Nucleoside/Nucleotide Analogs (NRTIs) Health. It displays or names all formulations of each HIV or HCV medication currently or recently available. Medications on the chart are listed in the Combivir Retrovir Trizivir Videx, Videx EC Zerit following manner: (/lamivudine) (zidovudine ZDV or AZT) (abacavir/lamivudine/zidovudine) ( or ddl) ( or d4T) • Grouped by class • Commercial brand name in bold • Formal clinical name (in parentheses), which may also be the name used in studies/trials before a medication received FDA approval and became available to the public Protease Inhibitors (PIs) CRI updates the chart as needed, with the date of each version noted. Aptivus Crixivan Invirase Kaletra Lexiva Viracept Copies are available upon request. For more information or to order copies ( or TPV) ( or IDV) ( or SQV) (/ritonavir) ( or FPV) (nel navir or NFV) of the chart, please contact the CRI Development and Communications oce at [email protected] or 617.502.1726. 617.502.1700 | www.crine.org

Non-Nucleosides (NNRTIs) Entry Inhibitors Integrase Inhibitors Visit our website at www.crine.org

Rescriptor Viramune Fuzeon Vitekta ( or DLV) ( or NVP) ( or ENF) (elvitegravir) (for injection) 529 Main Street, Suite 301, Boston, MA 02129 617.502.1700 Produced with support from the Bureau of Infectious Disease, Oce of HIV/AIDS, Massachusetts Department of Public Health. © 11/19

Top View